Former MitoKor Chairman and CEO to Lead R&D Programs Focused on Next-Generation Drug Discovery and Development

MENLO PARK, Calif. – March 14, 2005 – SRI International, an independent nonprofit research and development organization, today announced that Walter H. Moos, Ph.D., has joined SRI as vice president of its Biosciences Division. In this role, Dr. Moos will direct the institute's pharmaceutical and biotechnology discovery and development teams, which conduct proprietary SRI research and provide contract R&D services to government and commercial clients.  Dr. Moos will also oversee a business group that seeks partners, alliances and out-licensing opportunities.

Dr. Moos brings to SRI more than 20 years of pharmaceutical and biotechnology experience, including 14 years as a senior executive.  "Walter Moos' experience will provide the leadership, vision and operational expertise needed to continue our excellent record of meeting our clients' needs through state-of-the-art R&D," said Curt Carlson, Ph.D., SRI president and CEO.  "In addition, SRI is creating new approaches and forming innovative partnerships for the next generation of drug discovery and development. I am delighted that Walter has chosen to join SRI, where he will make a significant impact in moving forward these many opportunities."

At SRI, Dr. Moos will oversee the Biosciences Division, which has programs in cancer, endocrinology, immunology, infectious disease and neurosciences.   These programs include basic research into disease mechanisms, the discovery and validation of novel pharmaceutical targets, the identification and optimization of lead compounds as modulators of drug targets, and preclinical development projects that focus on advancing new chemical and biological candidates through regulatory filings and into Phase I human clinical evaluation.

During Dr. Moos' career, he has made significant contributions to all stages of drug discovery and development, including basic research, preclinical and clinical development, and product commercialization. Most recently, he was chairman and CEO of MitoKor, Inc. in San Diego. Previously, he was a corporate vice president at Chiron Corp., where he also held positions including Director of Chemical Therapeutics and Vice President of R&D in the Technologies Division. Earlier in his career, he held various positions at the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Co., last serving as Vice President, Neuroscience and Biological Chemistry.

Dr. Moos serves on the boards of directors of Alnis, Anterion, MIGENIX, Oncologic, Rigel and the Keystone Symposia. He is a co-founding member of the CEO Council, advisors to Red Abbey Venture Partners. He has served on the boards of Axiom Biotechnologies, the Biotechnology Industry Organization, CMPS, Mimotopes and Onyx. He also has served as a member of a number of academic and government advisory boards and committees.

Dr. Moos has a Ph.D. in chemistry from the University of California, Berkeley and received an A.B. in honors chemistry, cum laude, from Harvard University. He has held adjunct faculty positions at the University of Michigan, Ann Arbor, and since 1992 has been an Adjunct Professor at the University of California, San Francisco. He also has edited four books, helped to found multiple scientific journals, published more than 90 manuscripts and is a co-inventor on more than 30 issued U.S. patents.

About SRI International's Biosciences Division
For more than 40 years, SRI's Biosciences Division ( www.sri.com/pharma ) has conducted life sciences R&D and provided services to the National Institutes of Health and to pharmaceutical companies worldwide. The Division provides clients with a broad range of preclinical drug discovery and development capabilities, including medicinal chemistry, custom synthesis, efficacy pharmacology and GLP (good laboratory practices) safety evaluation, pharmacokinetics and metabolism studies, analytical chemistry and formulation design, drug product manufacturing in a cGMP (current good manufacturing practices) environment and regulatory support.

The Division specializes in cancer, endocrinology, immunology, infectious disease and neurosciences research.  SRI is a leader in the development of new products for the diagnosis and treatment of major diseases. SRI currently has two drugs on the market, three drugs and one imaging agent in clinical trials, and has assisted in the development of more than 130 other products currently in clinical trials or on the market.

About SRI International
Silicon Valley-based SRI International ( www.sri.com ) is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for almost 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships and creates spin-off companies.

# # #